The Japanese group licenses sapablursen from Ionis for $280m.
ApexOnco Front Page
Recent articles
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
